Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Surged Today

By Joe Tenebruso – Jul 20, 2020 at 7:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company received regulatory clearance to begin a new coronavirus-related study.

What happened

Shares of Sorrento Therapeutics (SRNE) jumped 20% on Monday after the biopharmaceutical company said regulators greenlighted a clinical trial for Abivertinib, a novel small molecule tyrosine kinase inhibitor.  

So what

On May 21, 2020, Sorrento reached an exclusive license agreement with ACEA Therapeutics for Abivertinib "across all indications for all territories outside of China."

Today, the Food and Drug Administration cleared Sorrento to begin a Phase 2 trial of Abivertinib in COVID-19 patients with moderate to severe lung-related symptoms.

A person points to a green upwardly sloping line that's above a red flat line.

Image source: Getty Images.

Abivertinib has shown potent immune system modulating effects in vitro, and Sorrento believes that it could potentially help prevent the "cytokine storm" -- an overreaction of the body's immune system that causes the body to attack its own cells -- in COVID-19 patients.

Now what

Sorrento Therapeutics' Phase 2 study will test the efficacy and safety of Abivertinib in patients with moderate to severe cases of COVID-19 who are hospitalized with developing cytokine storms in their lungs.

Abivertinib is expected to be generally safe, as it has already been studied in more than 600 cancer patients, with only low-grade adverse effects reported.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.